Monitoring osteoporosis therapies

Current Osteoporosis Reports

Volumn 5, Issue 1, 2007, Pages 38-43

  Miller, Paul D ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; ESTROGEN; ETIDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; TILUDRONIC ACID;

BONE DENSITY; BONE TURNOVER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; FRACTURE; HUMAN; META ANALYSIS; MORBIDITY; MORTALITY; NONHUMAN; OSTEOLYSIS; PATIENT ASSESSMENT; PATIENT CARE; PATIENT MONITORING; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); TERIPARATIDE; TREATMENT FAILURE;

EID: 33947424756     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/BF02938621     Document Type: Review

References (53)

1. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH: Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005, 16:372-379.
2. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N Engl J Med 1997, 337:670-676.
3. Bischoff-Ferrari HA, Willett WC, Wong JB, et al.: Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.
4. Black DM, Cummings SR, Karpf DB, et al.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996, 348:1535-1541.
5. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
6. Chesnut CH III, Skag A, Christiansen C, et al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19:1241-1249.
7. Chesnut CH III, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. Am J Med 2000, 102:267-276.
8. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
9. Tosteson AN, Grove MR, Hammond CS, et al.: Early discontinuation of treatment for osteoporosis. Am J Med 2003, 115:209-216.
10. Miller NH: Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997, 102:43-49.
11. Miller PD, Hochberg MC, Wehren LE, et al.: How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005, 21:545-553.
12. Miller PD: Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005, 3:103-110. This is a recent review of the value of surrogate markers of bone turnover and how they can be used in clinical practice to assess efficacy of osteoporosis therapy.
13. Bonnick SL, Shulman L: Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006, 119(4 Suppl 1):S25-S31.
14. Lewiecki EM: Nonresponders to osteoporosis therapy. J Clin Densitom 2003, 6:307-314.
15. Caro JJ, Isaac KJ, Huybrechts KF, et al.: The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004, 15:1003-1008.
16. Siris E, Harris ST, Rosen CJ, et al.: Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006, 81:1013-1022. This is a review of two large US databases showing the relationship between adherence to osteoporosis therapy and the rate of atraumatic fracture.
17. Cram P, Schlechte J, Christensen A: A randomized trial to assess the impact of direct reporting of DXA scan results to patients on quality of osteoporosis care. J Clin Densitom 2006, 9:393-398.
18. Dowd R, Recker RR, Heaney RP: Study subjects and ordinary patients. Osteoporos Int 2000, 11:533-536.
19. Lenchik L, Leib ES, Hamdy RC, et al.; International Society for Clinical Densitometry Position Development Panel and Scientific Advisory Committee: Executive summary International Society for Clinical Densitometry Position Development Conference Denver, Colorado, July 20-22, 2001. J Clin Densitom 2002, 5(suppl):S1-S3.
20. Cummings SR, Parfitt AM: Bone density regression to the mean and the individual patient. J Clin Endocrinol Metab 2001, 86:4001-4002.
21. Lenchik L, Watts NB: Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis. J Clin Densitom 2001, 4:1-4.
22. Chapurlat RD, Palmero L, Ramsay P, Cummings SR: Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 2005, 16:842-848.
23. Watts NB, Guesens P, Barton IP, Felsenberg D: Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005, 20:2097-2104.
24. Wasnich RD, Miller PD: Antifracture efficacy of antiresorptive agents are [sic] related to changes in bone density. J Clin Endocrinol Metab 2000, 85:231-236.
25. Cummings SR, Karpf DB, Harris F, et al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am J Med 2002, 112:281-289.
26. Hochberg MC, Greenspan SL, Wasnich RD, et al.: Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002, 87:1586-1592.
27. Chen P, Miller PD, Delmas PD, et al.: Change in lumbar spine bone mineral density and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res 2006, 21:1785-1790. Description of a new statistical method to examine the relationship between changes in bone mineral density and the reduction of fracture risk with teriparatide therapy.
28. Lewiecki EM, Miller PD, Leib ES, Bilezikian JP: Response to "The Perspective of the International Osteoporosis Foundation on the Official Positions of the International Society for Clinical Densitometry," by John A Kanis et al. [comment]. J Clin Densitom 2005, 8:143-144.
29. Bonnick SL, Johnston CC Jr, Kleerekoper M, et al.: Importance of precision in bone density measurements. J Clin Densitom 2001, 4:105-110.
30. Delmas PD, Eastell R, Garnero P, et al. for the Committee of Scientific Advisors of the International Osteoporosis Foundation: A position paper on the use of biochemical markers of bone turnover in osteoporosis. Osteoporosis Int 2000, 11(S6):S2-S17.
31. Miller PD, Baran DT, Bilezikian JP, et al.: Practical clinical application of biochemical markers of bone turnover. J Clin Densitom 1999, 2:323-342.
32. Riggs BL: Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients? [editorial]. Bone 2000, 26:551-552.
33. Garnero P, Delmas PD: Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women [review]. J Musculoskelet Neuronal Interact 2004, 4:50-63.
34. Eastell R, Barton I, Hannon RA, et al.: Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003, 18:1051-1056.
35. Bauer DC, Black DM, Garnero P, et al.: Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004, 19:1250-1258.
36. Greenspan SL, Resnick NM, Parker RA: Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2005, 90:2762-2767.
37. Schousboe JT, Bauer DC, Nyman JA, et al.: Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007, 18:201-210.
38. Bauer DC, Garnero P, Hochberg MC, et al. for the Intervention Research Group: Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 2006, 21:292-299.
39. Recker R, Stakkestad JA, Chesnut CH 3rd, et al.: Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 2004, 34:890-899.
40. Ste-Marie LG, Sod E, Johnson T, Chines A: Five years treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004, 75:469-476.
41. Recker RR: Alendronate effects on histomorphometric parameters: is there evidence for over-suppression of bone turnover? [abstract]. J Bone Miner Res 2005, M358:S398.
42. Miller PD, Bilezikian JP, Deal C, et al.: Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004, 10:139-148.
43. Hodsman AB, Bauer DC, Dempster D, et al.: Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 10:2004-2006.
44. Zanchetta JR, Bogado CE, Ferretti JL, et al.: Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003, 18:539-543.
45. Uusi-Rasi K, Semanick LM, Zanchetta JR, et al.: Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
46. Chen P, Satterwhite JH, Licata AA, et al.: Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005, 20:962-970.
47. Dobnig H, Sipos A, Jiang Y, et al.: Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005, 90:3970-3977.
48. Lewiecki EM, Laster A: Clinical review: clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab 2006, 91:4215-4222. A thorough review of the science and clinical application of vertebral fracture assessment by DXA for the identification of vertebral fractures.
49. Lindsay R, Silverman SL, Cooper C, et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001, 285:320-323.
50. Gallagher JC, Genant HK, Crans GG, et al.: Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005, 90:1583-1587.
51. Delmas P, Genant HK, Crans GG, et al.: Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003, 33:522-532.
52. Vokes T, Bachman D, Baim S, et al.; International Society for Clinical Densitometry: Vertebral fracture assessment: the 2005 ISCD Official Positions. J Clin Densitom 2006, 9:37-46.
53. Lewiecki EM, Binkley N, Petak SM: DXA quality matters. J Clin Densitom 2006, 9:388-392. A landmark study showing that quality control and proper interpretation are vital to the clinical implementation of DXA scans.